National Institute of Allergy And Infectious Diseases; Notice of Closed Meeting, 76374-76375 [2016-26388]
Download as PDF
<![CDATA[
76374
Federal Register / Vol. 81, No. 212 / Wednesday, November 2, 2016 / Notices
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Elena Smirnova, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5187,
MSC 7840, Bethesda, MD 20892, 301–435–
1236, smirnove@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Molecular and Cellular Aspects of
Nutrition, Obesity and Diabetes.
Date: November 29, 2016.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Raul Rojas, Ph.D.,
Scientific Review Officer, Scientific Review
Officer, Center for Scientific Review, 6701
Rockledge Drive, Room 6185, Bethesda, MD
20892, (301)451–6319, rojasr@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–12–
251: Behavioral Science Track Award for
Rapid Transition Review.
Date: December 2, 2016.
Time: 1:30 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Wind Cowles, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3172,
Bethesda, MD 20892, cowleshw@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 27, 2016.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–26454 Filed 11–1–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
sradovich on DSK3GMQ082PROD with NOTICES
National Institutes of Health
[FR Doc. 2016–26387 Filed 11–1–16; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
17:18 Nov 01, 2016
Jkt 241001
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel.
Date: November 4, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Cathy J. Wedeen, Ph.D.,
Scientific Review Officer, Division of
Scientific Review, OD, Eunice Kennedy
Shriver National Institute of Child Health
and Human Development, NIH, DHHS,
6710B Rockledge Drive, Bethesda, MD 20892,
301–435–6878, wedeenc@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; Multivariate
Genetics & Genomics of Reading &
Comprehension & Related Cognition.
Date: November 28, 2016.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6710 B
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Marita R. Hopmann, Ph.D.,
Scientific Review Officer, Division of
Scientific Review, National Institute of Child
Health and Human Development, 6710B
Rockledge Drive, Bethesda, MD 20892, (301)
435–6911, hopmannm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
Dated: October 27, 2016.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
Eunice Kennedy Shriver National
Institute Of Child Health & Human
Development; Notice of Closed
Meetings
VerDate Sep<11>2014
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
BILLING CODE 4140–01–P
PO 00000
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy And
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
Division of Intramural Research Board
of Scientific Counselors, NIAID.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Institute of Allergy and
Infectious Diseases, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Division of Intramural
Research Board of Scientific Counselors,
NIAID.
Date: December 12–14, 2016.
Time: December 12, 2016, 7:45 a.m. to 5:45
p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 50, Louis Stokes Laboratories,
Conference Rooms 1227/1233, 50 Center
Drive, Bethesda, MD 20892.
Time: December 13, 2016, 7:30 a.m. to 5:00
p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 50, Louis Stokes Laboratories,
Conference Rooms 1227/1233, 50 Center
Drive, Bethesda, MD 20892.
Time: December 14, 2016, 7:00 a.m. to
Adjournment.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health,
Building 50, Louis Stokes Laboratories,
Conference Rooms 1227/1233, 50 Center
Drive, Bethesda, MD 20892.
Contact Person: Steven M. Holland, MD,
Ph.D., Chief, Laboratory of Clinical Infectious
Diseases, National Institutes of Health/
NIAID, Hatfield Clinical Research Center,
Bethesda, MD 20892–1684, 301–402–7684,
sholland@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Frm 00044
Fmt 4703
Sfmt 4703
E:\FR\FM\02NON1.SGM
02NON1
Federal Register / Vol. 81, No. 212 / Wednesday, November 2, 2016 / Notices
Dated: October 26, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–26388 Filed 11–1–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
Internet at https://www.samhsa.gov/
workplace.
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, 5600
Fishers Lane, Room 16N03A, Rockville,
Maryland 20857; 240–276–2600 (voice).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
sradovich on DSK3GMQ082PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:18 Nov 01, 2016
Jkt 241001
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
specimen validity tests on urine
specimens for federal agencies.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that it has met minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following HHScertified laboratories and IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
HHS-Certified Instrumented Initial
Testing Facilities
Dynacare, 6628 50th Street NW.,
Edmonton, AB Canada T6B 2N7, 780–
784–1190, (Formerly: GammaDynacare Medical Laboratories).
HHS-Certified Laboratories
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264.
Aegis Analytical Laboratories, Inc., 345
Hill Ave., Nashville, TN 37210, 615–
255–2400, (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc., Aegis Analytical
Laboratories).
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.).
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.).
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center).
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
76375
Clinical Reference Laboratory, Inc., 8433
Quivira Road, Lenexa, KS 66215–
2802, 800–445–6917.
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890.
Dynacare*, 245 Pall Mall Street,
London, ONT, Canada N6A 1P4, 519–
679–1630, (Formerly: GammaDynacare Medical Laboratories).
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609.
Fortes Laboratories, Inc., 25749 SW.
Canyon Creek Road, Suite 600,
Wilsonville, OR 97070, 503–486–
1023.
Laboratory Corporation of America
Holdings, 7207 N. Gessner Road,
Houston, TX 77040, 713–856–8288/
800–800–2387.
Laboratory Corporation of America
Holdings, 69 First Ave., Raritan, NJ
08869, 908–526–2400/800–437–4986,
(Formerly: Roche Biomedical
Laboratories, Inc.).
Laboratory Corporation of America
Holdings, 1904 Alexander Drive,
Research Triangle Park, NC 27709,
919–572–6900/800–833–3984,
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory; Roche
CompuChem Laboratories, Inc., A
Member of the Roche Group).
Laboratory Corporation of America
Holdings, 1120 Main Street,
Southaven, MS 38671, 866–827–8042/
800–233–6339, (Formerly: LabCorp
Occupational Testing Services, Inc.;
MedExpress/National Laboratory
Center).
LabOne, Inc. d/b/a Quest Diagnostics,
10101 Renner Blvd., Lenexa, KS
66219, 913–888–3927/800–873–8845,
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of
LabOne, Inc.).
MedTox Laboratories, Inc., 402 W.
County Road D, St. Paul, MN 55112,
651–636–7466/800–832–3244.
MetroLab-Legacy Laboratory Services,
1225 NE 2nd Ave., Portland, OR
97232, 503–413–5295/800–950–5295.
Minneapolis Veterans Affairs Medical
Center, Forensic Toxicology
Laboratory, 1 Veterans Drive,
Minneapolis, MN 55417, 612–725–
2088, Testing for Veterans Affairs
(VA) Employees Only.
National Toxicology Laboratories, Inc.,
1100 California Ave., Bakersfield, CA
93304, 661–322–4250/800–350–3515.
One Source Toxicology Laboratory, Inc.,
1213 Genoa-Red Bluff, Pasadena, TX
77504, 888–747–3774, (Formerly:
E:\FR\FM\02NON1.SGM
02NON1
]]>Agencies
[Federal Register Volume 81, Number 212 (Wednesday, November 2, 2016)]
[Notices]
[Pages 76374-76375]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-26388]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy And Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
Division of Intramural Research Board of Scientific Counselors, NIAID.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the National
Institute of Allergy and Infectious Diseases, including consideration
of personnel qualifications and performance, and the competence of
individual investigators, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
Name of Committee: Division of Intramural Research Board of
Scientific Counselors, NIAID.
Date: December 12-14, 2016.
Time: December 12, 2016, 7:45 a.m. to 5:45 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Building 50, Louis Stokes
Laboratories, Conference Rooms 1227/1233, 50 Center Drive, Bethesda,
MD 20892.
Time: December 13, 2016, 7:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Building 50, Louis Stokes
Laboratories, Conference Rooms 1227/1233, 50 Center Drive, Bethesda,
MD 20892.
Time: December 14, 2016, 7:00 a.m. to Adjournment.
Agenda: To review and evaluate personal qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, Building 50, Louis Stokes
Laboratories, Conference Rooms 1227/1233, 50 Center Drive, Bethesda,
MD 20892.
Contact Person: Steven M. Holland, MD, Ph.D., Chief, Laboratory
of Clinical Infectious Diseases, National Institutes of Health/
NIAID, Hatfield Clinical Research Center, Bethesda, MD 20892-1684,
301-402-7684, sholland@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
[[Page 76375]]
Dated: October 26, 2016.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-26388 Filed 11-1-16; 8:45 am]
BILLING CODE 4140-01-P
